Casey v. Merck & Co., Inc.

Supreme Court of Virginia·Decided March 2, 2012·No. 111438·Published

Opinion

Present: All the Justices

JOHN CASEY, INDIVIDUALLY AND AS ADMINISTRATOR OF THE ESTATE OF ORA CASEY, ET AL.

OPINION BY

v. Record No. 111438 JUSTICE S. BERNARD GOODWYN March 2, 2012

MERCK & CO., INC.

UPON QUESTIONS OF LAW CERTIFIED BY THE UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

Pursuant to Article VI, Section 1 of the Constitution of Virginia and our Rule 5:40, we accepted the following certified questions from the United States Court of Appeals for the Second Circuit:

(1) Does Virginia law permit equitable tolling of a state statute of limitations due to the pendency of a putative class action in another jurisdiction?

(2) Does Va. Code Ann. § 8.01-229(E)(1) permit tolling of a state statute of limitations due to the pendency of a putative class action in another jurisdiction?

Background

On September 15, 2005, a putative class action, Wolfe v.

Merck & Co., was filed in the United States District Court for the Middle District of Tennessee. The putative class included "[a]ll persons who consume or have consumed FOSAMAX, whether intravenously or by mouth." The representative plaintiffs in the class action asserted claims of strict liability, negligence and medical monitoring against Merck & Co., Inc. (Merck).

The Wolfe putative class action was transferred to the United States District Court for the Southern District of New York by the Judicial Panel on Multidistrict Litigation, which consolidated certain Fosamax cases. The Southern District of New York denied class certification and dismissed the Wolfe class action on January 28, 2008.

Prior to the dismissal of the Wolfe putative class action, four plaintiffs, all residents of Virginia, filed individual state law based actions against Merck in the Southern District of New York, asserting federal diversity jurisdiction. All four plaintiffs allegedly suffered from osteonecrosis of the jaw as a result of taking Fosamax. The district court noted that "[i]t is undisputed that all four plaintiffs filed suit more than two years after the latest possible date that they sustained their respective alleged injuries," and that Virginia law applied to the claims.

Merck moved for summary judgment, alleging that the four plaintiffs’ actions were untimely under Virginia's two-year statute of limitations for personal injuries. In response, the plaintiffs claimed that the Wolfe putative class action, which was filed within the two-year limitation period, tolled the running of the Virginia statute of limitations on their individual actions because they would have been members of the proposed class had certification been granted. The district

court granted Merck's motion, finding that the pendency of the Wolfe putative class action did not toll Virginia's limitations period for the four plaintiffs' state law claims.

The plaintiffs appealed to the United States Court of Appeals for the Second Circuit. The Second Circuit determined that Virginia law governed whether the Wolfe putative class action tolled the running of the statute of limitations on the plaintiffs' individual claims, and asked this Court to determine whether Virginia law permits equitable or statutory tolling of a Virginia statute of limitations due to the pendency of a putative class action in another jurisdiction.

Facts

The relevant facts, as set forth in the certification order, are not in dispute. Merck manufactures Fosamax, a prescription drug that falls within a class of drugs known as bisphosphonates, which are used to treat bone conditions such as osteoporosis. Fosamax, a nitrogenous bisphosphonate, has allegedly been linked to osteonecrosis – bone death – of the jaw.

The four plaintiffs were prescribed and consumed Fosamax.

Rebecca Quarles was diagnosed with osteonecrosis of the jaw and failure of dental implants in 2003 and sued Merck in 2007. Dorothy Deloriea was prescribed and took Fosamax in 1999, developed osteomyelitis and osteonecrosis of the jaw in 2004,

and filed her complaint against Merck in 2008. Ora Casey began taking Fosamax in 2000 and was diagnosed with osteonecrosis of the jaw in 2004. She died in 2007 and her estate initiated this action in 2008. Roberta Brodin was prescribed and took Fosamax in 2001 and was diagnosed with osteonecrosis of the jaw in 2005. She initiated her action in 2007.

The plaintiffs' complaints against Merck assert exclusively Virginia state law claims: strict liability, failure to warn, breach of express and implied warranty, and negligence in the design, testing, development, manufacture, labeling, marketing, distribution and sale of Fosamax. As a result, it is agreed that Virginia law governs the question of whether the filing of the putative class tolled the running of the statute of limitations on their claims.

Analysis

The two certified questions of law relate to Virginia's statute of limitations for personal injury actions. ∗ "[T]he applicability of the statute of limitations is a purely legal question of statutory construction." Conger v. Barrett, 280 Va. 627, 630, 702 S.E.2d 117, 118 (2010).

Code § 8.01-243(A) provides: "every action for personal injuries, whatever the theory of recovery . . . shall be brought within two years after the cause of action accrues."

The plaintiffs contend that Virginia law permits equitable tolling of a Virginia statute of limitations based upon the filing of a cross-jurisdictional putative class action. Plaintiffs also argue that the pendency of a putative class action in another jurisdiction statutorily tolls Virginia's statute of limitations under Code § 8.01-229(E)(1). Merck responds that Virginia law does not permit equitable tolling of a statute of limitations, and that Code § 8.01-229(E)(1) does not provide for tolling due to the pendency of a putative class action in another jurisdiction.

Certified Question (1)

It is well-established that "statutes of limitations are strictly enforced and must be applied unless the General Assembly has clearly created an exception to their application." Rivera v. Witt, 257 Va. 280, 283, 512 S.E.2d 558, 559 (1999). A statute of limitations may not be tolled, "or an exception applied, in the absence of a clear statutory enactment to such effect." Arrington v. Peoples Sec. Life Ins. Co., 250 Va. 52, 55-56, 458 S.E.2d 289, 291 (1995). "[A]ny doubt must be resolved in favor of the enforcement of the statute." Id. at 55, 458 S.E.2d at 290-91.

Given these principles, there is no authority in Virginia jurisprudence for the equitable tolling of a statute of limitations based upon the pendency of a putative class action

in another jurisdiction. Certified Question (1) is answered in the negative.

Certified Question (2)

Code § 8.01-229(E)(1) provides that "if any action is commenced within the prescribed limitation period and for any cause abates or is dismissed without determining the merits, the time such action is pending shall not be computed as part of the period within which such action may be brought, and another action may be brought within the remaining period." The plaintiffs contend that Code § 8.01-229(E)(1) statutorily tolled the statute of limitations for plaintiffs’ claims during the pendency of the putative class action. The plaintiffs assert that this Court's decision in Welding, Inc. v. Bland Cnty. Serv. Auth., 261 Va. 218, 541 S.E.2d 909 (2001), indicates that Virginia should recognize cross-jurisdictional putative class action tolling.

Free access — add to your briefcase to read the full text and ask questions with AI

Casey v. Merck & Co., Inc., (Va. 2012).

Casey v. Merck & Co., Inc. (Casey v. Merck & Co., Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

American Pipe & Construction Co. v. Utah
414 U.S. 538 (Supreme Court, 1974)
Conger v. Barrett
702 S.E.2d 117 (Supreme Court of Virginia, 2010)
Harmon v. Sadjadi
639 S.E.2d 294 (Supreme Court of Virginia, 2007)
Braddock v. BD. OF SUP'RS OF LOUDOUN
601 S.E.2d 552 (Supreme Court of Virginia, 2004)
Brake v. Payne
597 S.E.2d 59 (Supreme Court of Virginia, 2004)
Fowler v. Winchester Medical Center, Inc.
580 S.E.2d 816 (Supreme Court of Virginia, 2003)
Welding, Inc. v. Bland County Service Authority
541 S.E.2d 909 (Supreme Court of Virginia, 2001)
Rivera v. Witt
512 S.E.2d 558 (Supreme Court of Virginia, 1999)
W. S. Carnes, Inc. v. Board of Supervisors
478 S.E.2d 295 (Supreme Court of Virginia, 1996)
Arrington v. Peoples Security Life Insurance
458 S.E.2d 289 (Supreme Court of Virginia, 1995)
McDaniel v. North Carolina Pulp Co.
95 S.E.2d 201 (Supreme Court of Virginia, 1956)
Harbour Gate Owners' Ass'n v. Berg
348 S.E.2d 252 (Supreme Court of Virginia, 1986)